Richter Gives Lilly Estetrol Combination Rights, Keeping a US Option on FYLREVY

What happened

Gedeon Richter has licensed worldwide rights to estetrol combinations to Eli Lilly. Lilly receives exclusive rights to develop estetrol combinations in two areas: women's health and cardiometabolic disease. It also receives an option to co-commercialise Richter's FYLREVY in the US, and will buy about $15M of Richter shares.

The material available to us does not disclose upfront payments, milestones, royalties, the development plan or the option's exercise terms. Any valuation of the deal would be speculation. What can be assessed is its architecture: a field-limited licence, a commercial option and a small equity investment.

The strategic logic

The licence covers combinations, not estetrol as a standalone product. That points to a development thesis in which estetrol is paired with other agents, and the two named fields suggest the partners see relevance beyond women's health alone. The pairing of women's health with cardiometabolic disease is the most distinctive element of the announcement, and the combination programmes it enables are the part to watch.

For Richter, the deal lets it monetise and extend an asset through a larger partner's development capacity without ceding everything. The licence is field-limited, and the US co-commercialisation option attaches to FYLREVY, a product Richter already owns. Whether Lilly exercises it will show how seriously it views the US commercial opportunity.

For Lilly, the structure is a flexible entry. It gets development rights in defined indications and a call on a US commercial role, rather than a full acquisition of an asset. An option reduces commitment until there is more clarity on FYLREVY's trajectory.

Reading the equity component

The roughly $15M share purchase is modest and should not be over-read. Equity investments in licensing deals typically serve as an alignment signal, giving the larger partner a stake in the licensor's success. We have no information on pricing, premium or lock-up terms, so any claim of a vote of confidence is interpretation, not fact.

Competitive and market context

The deal sits within a week of filings showing how varied dealmaking is across the sector. At the top end, Silence Therapeutics reported a $12.4M third-quarter loss and $247.7M in cash, alongside positive Phase 2 divesiran data in polycythemia vera and a pending acquisition by Merck KGaA. That is clinical data converting into an outright sale.

Further down the capital ladder, smaller companies are using transactions to survive or refocus. MacroGenics reports $288M in cash and a 2028 runway, helped by non-dilutive deals including a manufacturing sale and a ZYNYZ royalty sale, and is putting its B7-H3 ADC MGC026 in head and neck cancer first. Theriva sold its SYN-004 antibiotic-enzyme assets to Biossil Labs for $350,000 upfront while pushing VIRAGE2 enrolment in metastatic pancreatic cancer toward completion in the fourth quarter of 2026. Longeveron, after laromestrocel missed its primary endpoint in ELPIS II, has begun a strategic alternatives review that could end in a sale or merger. Xenetic plans a Q1 2027 close on its all-stock Santersus acquisition, reporting about $0.7M in royalty revenue and $5.8M in cash.

Kiora's in-licensing of Senju's oral calpain inhibitor KIO-401 (mitucapistat) for retinal artery occlusion, with rights outside Asia, is another example of the field-limited, geography-limited licence structure that Richter and Lilly have also used.

Risks and open questions

Development risk is the first. Combination programmes across two therapeutic areas mean multiple trials and multiple regulatory paths. The material says nothing on stage, timelines or the agents that estetrol would be combined with.

Commercial risk is second. An option is not a commitment. If Lilly does not exercise its US co-commercialisation right on FYLREVY, Richter would need its own US route. Because the option is Lilly's to take, Richter bears the uncertainty.

Third is the concentration of undisclosed terms. Without upfront and milestone figures, the market cannot gauge how much value Richter captured or how much risk Lilly took on. Richter's own disclosures in coming periods may add detail.

What to watch

Watch for disclosure of financial terms and for the first named combination programmes, particularly whether women's health or cardiometabolic disease moves first. Also watch for any signal on Lilly's FYLREVY option, and for further partnerships from Richter around estetrol. Finally, the pace at which smaller developers like those above pursue licensing, divestment and merger routes will shape the supply of assets for larger buyers.